Tenderwize
Back to tender search

Open-House-Biologika-Rabattverträge 2025-15

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 343 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of Trastuzumab (subcutaneous injection) under a discount contract with German statutory health insurance funds.
  • Conclusion of a framework-type agreement without volume commitment; no exclusivity for any contractor.
Show full summary

Open-House procedure by German health insurance funds (led by Techniker Krankenkasse) for discount contracts on Trastuzumab (subcutaneous injection). The procedure is open to all eligible pharmaceutical entrepreneurs throughout the contract term (max. 24 months, 01.08.2025 – 31.07.2027). No estimated contract value is provided; the procedure is not a public procurement subject to EU procurement law but a voluntary publication. Participation is possible at any time during the contract term, with specific deadlines for inclusion in the monthly pharmacy software update.

Risks

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the specific drug.
  • Must have a valid marketing authorization for Trastuzumab (subcutaneous injection) in Germany.

Eligibility

  • Must provide a self-declaration confirming eligibility and reliability.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-15

Single lot covering discount contracts for Trastuzumab (subcutaneous injection). All eligible pharmaceutical entrepreneurs can conclude a contract under uniform conditions; no exclusivity is granted. The contract ends at the latest on 31.07.2027, or earlier upon patent expiry/market exclusivity loss.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Award Criteria

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Deadline

Deadline Jul 30, 2027

Procurement Details

Publication date
19 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
323734-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9